Evidence map›Paper›PMID 42873406›Full record

ArticleCEN case reports2026

Severe growth retardation in Dent disease: a case report of a novel OCRL variant.

Okan Akacı, Erdal Eren

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Okan AkacıPediatric Nephrology Unit, University of Health Sciences Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey. okanakaci@gmail.com.
Erdal ErenDepartment of Pediatric Endocrinology, Bursa Uludağ University, Bursa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDent disease type 2 (DD-2) is a rare X-linked recessive renal tubulopathy caused by mutations in the OCRL gene. Clinically it is characterised by low molecular weight proteinuria (LMWP), hypercalciuria, and nephrocalcinosis. The phenotypic spectrum of DD-2 is expanding with the identification of new pathogenic variants. CASE REPORT: A 12-year-old male presenting with marked short stature and poor weight gain was found to have LMWP, haematuria, hypercalciuria, and bilateral nephrocalcinosis on initial clinical evaluation. Renal function was normal. There was no relevant family history. Genetic analysis revealed a hemizygous missense variant (c.899 C > A; p.Ala300Asp) in the OCRL gene, which has not been previously reported in the literature. No abnormalities were found on ocular or neurological examination as the same gene also causes Lowe syndrome. Therefore DD-2 was considered in this patient. Hydrochlorothiazide treatment was initiated but discontinued due to hypokalaemia. Growth hormone therapy was started by the endocrinology clinic due to severe growth retardation.

conclusionDent disease can present with a wide range of clinical findings. This case report describes a novel OCRL gene variant associated with DD-2. This newly identified variant contributes to the genotypic and phenotypic diversity of the disease, however, without functional validation, it is difficult to determine whether growth retardation is a significant complication in DD-2. Early diagnosis and a multidisciplinary approach are crucial for improving long-term outcomes.

Indexed as

Dent DiseaseGrowth DisordersNephrolithiasisPhosphoric Monoester HydrolasesChildGenetic Diseases, X-LinkedHematuriaHuman Growth HormoneHumansHydrochlorothiazideHypercalciuriaHypokalemiaMaleMutation, MissenseNephrocalcinosisOculocerebrorenal SyndromeHuman Growth HormoneHydrochlorothiazideOCRL protein, humanPhosphoric Monoester Hydrolases

Identifiers

PMID42873406
PMCPMC13669284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.